The recognition of altered immune system function in many chronic disease states has proven to be a pivotal advance in biomedical research over the past decade. For many metabolic and mood disorders, this altered immune activity has been characterized as inflammation, with the attendant assumption that the immune response is aberrant. However, accumulating evidence challenges this assumption and suggests that the immune system may be mounting adaptive responses to chronic stressors. Further, the inordinate complexity of immune function renders a simplistic, binary model incapable of capturing critical mechanistic insights. In this perspective article, we propose alternative paradigms for understanding the role of the immune system in chronic disease. By invoking allostatic or systems biology rather than inflammation, we can ascribe greater functional significance to immune mediators, gain newfound appreciation of the adaptive facets of altered immune activity, and better avoid the potentially disastrous effects of translating erroneous assumptions into novel therapeutic strategies.

**Introduction**

Depression and metabolic disease exhibit an interdependent relationship. Obesity and type 2 diabetes mellitus are associated with increased incidence of depression, and patients with depression are at increased risk for the development of metabolic disease. Though this relationship is poorly understood, the presence of altered immune system activity in both disorders may provide a key pathophysiologic link. Indeed, over the past 2 decades, changes in immune system activity have been identified as a hallmark feature of many chronic diseases, including depression, obesity, type 2 diabetes mellitus, atherosclerosis, and cancer. Common changes in immune function across these disorders may in part underlie their association in epidemiologic studies. These observations collectively have generated a novel paradigm, that of inflammation contributing to the initiation and progression of chronic disease. This paradigm has been pivotal for capturing critical insights about the dynamic regulation of immune function in a variety of disorders.

**Keywords:** allostatic; depression; diabetes; immunity; inflammation; obesity

**Author affiliations:** Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington, USA (Katya B. Rubinow); Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina, USA (David R. Rubinow)

**Address for correspondence:** Katya Rubinow, 850 Republican St, Box 358055, Seattle, Washington 98109, USA (email: rubinow@uw.edu)
Clinical research

Nevertheless, use of the term inflammation in depression and metabolic disease may also inadvertently encourage the continued use of explanatory models deprived of context. Specifically, the “inflammation” model engenders a binary understanding of biology, wherein inflammation is detrimental and its attenuation beneficial. This construct of inflammation as a unitary process thus fails to account for the exquisite complexity of the immune system, which comprises multiple cell types, each with the capacity to acquire highly heterogeneous phenotypes in different biological contexts. Consequently, describing the role of inflammation rather than the immune system in depression and metabolic disease may create a falsely comprehensive sense of understanding pathophysiology where significant uncertainty persists. So, too, may it obscure important differences in immune function in these respective disease states. Finally, the paradigm of inflammation fails to distinguish between immune system involvement and aberrant immune function, a critical distinction when identifying potential targets for therapeutic interventions. In the following paragraphs, we first describe observations that are discordant with the current perceived associations between depression or metabolic disease and inflammation. We then discuss the limitations of inflammation as a paradigm for describing the role of the immune system in disease states. Next, we suggest the potential dangers inherent in the conceptualization of immune function as inflammation, a value-laden construct that may obscure physiologic insights and thereby generate therapeutic interventions with unintended, adverse effects. Finally, we introduce alternative models—allostasis and systems biology—that may facilitate a more textured understanding of immune regulation in metabolic and mood disorders.

Inflammation and disease: a dissociable association

A causal relationship between changes in immune activity and depression is supported by the high prevalence of depressive syndromes among patients on interferon-α therapy, with 25% to 50% of patients on high-dose therapy meeting DSM-IV (Diagnostic and Statistical Manual of Mental Disorders [Fourth Edition]) criteria for major depression. Notably, many of these patients derive therapeutic benefit from selective serotonin reuptake inhibitors, offering further, indirect evidence that peripheral changes in cytokine exposure can alter central neurotransmitter signaling. In humans, illness or experimental administration of endotoxin can produce changes in mood and behavior characteristic of major depression. Similarly, animal studies demonstrate the precipitation of “depressive-like” behaviors after endotoxin administration in association with elevations of individual cytokines (eg, interleukin [IL]-1β, IL-6). Hodes et al further demonstrated that susceptibility to chronic stress–induced social avoidance in mice appeared to be mediated by excess peripheral IL-6 production. These observations are supported by extensive evidence of cytokine regulation of neurotransmitters central to mood and behavior. Thus, primary activation of the immune system can generate many of the behavioral, affective, and biochemical features of major depression. In turn, major depression is associated with altered immune system activity, as illustrated by increased circulating levels of the cytokine tumor necrosis factor-α (TNF-α) and IL-6. Elevated cytokine production is, unsurprisingly, not unique to depression but also has been reported for anxiety disorders including posttraumatic stress disorder. These findings have collectively led to the pivotal recognition that immune function may be altered in depression and related mood disorders and the growing interest in the use of anti-inflammatory therapies as a novel treatment strategy for major depression.

Despite these intriguing findings, dissociations between cytokine elevation and depression have been observed. For example, endotoxin administration to patients with severe depression resulted in the acute remission of depressive symptoms, and exercise augmentation produced significant antidepressant effects in the absence of changes in serum levels of TNF-α or IL-6. Similarly, in vitro and in vivo, pharmacologic antidepressant treatment has resulted in either paradoxical increases or no changes in the production of cytokines, including IL-6 and IL-1β. Further, anti-inflammatory agents have been shown to antagonize the behavioral and biochemical effects of selective serotonin reuptake inhibitors in mice and the antidepressant effects of these agents in humans. Observed dissociations between peripheral and central cytokine levels also underscore the limitations of making inferences about a local immune response on the basis of circulating markers. Notably, too, the specific cytokines reported as significantly elevated in depressed...
patients have differed across studies and may in part reflect the confounding effects of medical comorbidities commonly found among patients included in these studies. Finally, the overlap in serum cytokine levels between patients and controls is substantial. In their thoughtful review, Raison and Miller conclude that depression is not primarily an inflammatory disorder though they propose that inflammation probably contributes to a subset of depressive presentations. Nonetheless, even these more nuanced views may risk conceptually collapsing dynamic changes in immune activity to “inflammation.” This reductionist model could prevent more comprehensive understanding of underlying biology, including specificity with regard to cell type, time course, and, most critically, the adaptive and functional significance of an immune response.

As is true for depression, obesity and type 2 diabetes mellitus have been associated with elevated circulating cytokine levels and further may be characterized by increased infiltration of immune cells into metabolic tissues. In animal models, deficiency of TNF-α or chemokine (C-C motif) ligand 2 (CCL2) confers protection from diet-induced insulin resistance, and TNF-α can directly inhibit insulin signaling in vitro. These and similar observations have led to an analogous paradigm of metabolic disease as a state of chronic inflammation, with the attendant suggestion that immune function is dysregulated; therefore, immunomodulatory therapies may hold promise as treatment strategies. Again, however, the development of such treatments posits aberrant immune function as a driving etiologic force of metabolic disorders, a problematic concept for several reasons. First, the capacity to generate insulin resistance through pharmacologic cytokine exposures does not definitively demonstrate that dysregulated immune activity drives the insulin resistance associated with obesity. Second, an etiopathogenic role of inflammation is undermined by the failure to date of immune-targeted therapies in the treatment of metabolic disease. Third, as in depression, changes in serum cytokine levels are dissociable from the predicted metabolic phenotype. Thus, lipid infusion in human subjects generated insulin resistance in the absence of changes in circulating cytokines. In mice, IL-6 deficiency led to glucose intolerance and insulin resistance not seen in wild-type controls. In a model of diet-induced obesity, IL-6–deficient mice exhibited the same metabolic phenotype as wild-type controls, despite attenuated leukocytosis and serum amyloid A-1 (SAA-1) generation. In parallel, clinical use of an IL-6 receptor (IL-6R) neutralizing antibody led to metabolic dysregulation characterized by markedly increased weight, hypertriglyceridemia, and hypercholesterolemia. Collectively, these observations undermine existing, simplistic models that identify inflammation as both hallmark feature and pathogenic origin of metabolic and mood disorders. Moreover, they underscore the importance of determining not only a clinical syndrome but also the underlying disease, as defined by a distinct pathophysiology.

**Immune alterations: adaptation and maladaptation**

The inference that the immune system behaves aberrantly in metabolic disorders disregards the critical question of why altered immune function is observed in these disease states. As an alternative construct, the immune system could be mounting an adaptive response to the chronic stress of excess energy intake; the proliﬁc and antiadipogenic effects of TNF-α could be viewed as protective, antiobesity functions that may attenuate lipotoxicity or glucotoxicity at the cellular level. Indeed, obesity itself has been described as an adaptive effort to prevent lipotoxicity in extra-adipose tissue. Thus, even if one by-product of this response were the promotion of insulin resistance, immune-directed therapies could target adaptive responses rather than pathogenic triggers and pose a potential for harm magnified by the almost inevitable compromise of host defense conferred by such treatments. The complexity of physiologic responses to stressors is well illustrated by glucocorticoid activity in affective disorders. Thus, it is generally assumed that elevated glucocorticoid release corresponds to the relative physiologic overwhelm conferred by a stressor. This presumption, however, breaks down with consideration of the individual calibration of the hypothalamic-pituitary-adrenal (HPA) axis or the timing of cortisol elevation. The isolated use of serum cortisol levels, for example, would fail to capture the physiologic overwhelm of stress-dependent disorders like posttraumatic stress disorder, which commonly is associated with low cortisol levels but increased glucocorticoid receptor signaling in target tissues. Further, in striking contrast to the presumed deleterious effects of glucocorticoids, increased glucocorticoid exposure during or immediately before acute immobili-
The occurrence of adaptive and maladaptive sequelae also may be separated temporally. Obesity itself may be adaptive in certain contexts, as overeating could confer protective, stress-alleviating effects that contribute immediately to reproductive success, albeit at the expense of the individual’s long-term health. Thus, the perspective from which the biological system is observed must first be defined, as the same mediators may appear to confer maladaptive changes with regard to systemic glucose metabolism or clinical symptoms but nonetheless continue to play protective, adaptive roles with regard to cellular function and survival. This dynamic approach to understanding adaptation reflects the intricate network of biologic systems involved in any stress response. Adaptation entails not a linear progression of events but rather extensive crosstalk among multiple regulatory arms, including the immune system, sympathetic and parasympathetic nervous systems, and neuroendocrine systems. Yet, pharmacologic therapies are designed specifically to target a single locus within this vast regulatory framework. The attendant implication, then, is that such therapies are unlikely to restore an optimally adaptive state but have great potential to disrupt these signaling networks and thereby prevent or impede innate, adaptive responses.

**Complexity of immune responses: defying a binary nomenclature**

One obstacle to elucidating disease pathophysiology is the tendency to model disease states in terms of biological markers as opposed to biological mediators. Whereas mediators can play complex roles, markers are deprived of biological context and functional significance; they simply rise or fall, appear or disappear. As a result, markers fit neatly into paradigms predicated on binary or linear constructs, but the importance of assigning functional significance becomes increasingly evident as emergent data dismantle binary or linear understandings of immune function. Rather, a clear distinction between pro- and anti-inflammatory processes readily disappears when individual mediators and contextual variables are more closely examined. The dynamic functional properties of immune mediators are compellingly illustrated by prostanoid signaling. Induction of the enzyme cyclooxygenase 2 (COX-2), for example, generates lipid mediators that evolve both early and late in immune cell activation and function to both propagate and resolve the immune response. Although prostaglandin E₂ (PGE₂) promotes vasodilation and neutrophil chemotaxis, it also confers suppressive effects on T-cell proliferation and activation. Further, progressive accumulation of PGE₂ may be critical for the generation of resolvins and protectins, the lipid signals that help terminate an immune response. Thus, PGE₂ exerts complex effects and cannot be reduced to a simple pro- or anti-inflammatory designation as would be required by the rubric of inflammation.

As noted above, the effects of an individual immune mediator depend on critical variables, including the timing and magnitude of exposure, the specific cell and tissue type, and the presence of concurrent signals. The actions of an individual mediator, therefore, can only be understood within a defined biological context. The
time-dependent nature of paracrine signaling is illustrated by the adipokine adiponectin, which triggers an initial burst of nuclear factor-xB activity and cytokine secretion in macrophages. Subsequent to this transient activation, however, adiponectin-treated macrophages exhibit a substantially diminished response to endotoxin stimulation. The phenomenon of macrophage tolerance to endotoxin similarly illustrates that the cellular response to a given stimulus can differ markedly on the basis of previous exposure. Notably, too, endotoxin tolerance is characterized by reductions only in specific cytokines and can be abrogated completely when macrophages are pretreated with interferon-γ. These observations are complemented by the recent demonstration that previous exposure to a stressor dramatically and persistently alters the gene-expression profile resulting from a subsequent stressor, evidence of a reprogrammed cellular response. Even the kinetics of biological signaling are critical, as pulsatile versus sustained exposures elicit different genetic activation profiles, despite the same cumulative “dose of signal.” Further, as with PGE₂, the physiologic effects of other immune-derived mediators are concentration-dependent. In vitro data suggest that TNF-α diminishes insulin-stimulated glucose uptake at higher concentrations but actually augments adipocyte glucose uptake at lower concentrations. Moreover, the metabolic effects of TNF-α may be divergent across different tissue types, as TNF-α-deficient mice exhibited reduced lipid accumulation in liver but not skeletal muscle during high-fat feeding. Adding an additional layer of complexity, the magnitude of signal exposure encompasses not only the concentration of a mediator but also the relative expression of its receptor, cellular localization of the receptor, and flux in postreceptor pathways, which may undergo continual remodeling under different biological conditions. The heterogeneous effects of these individual mediators find parallel in the apparent paradox that metabolic and mood disorders represent states of both heightened immune system activity and relative immunosuppression. Thus, an ever-growing body of data refutes to conform to the extent understanding of inflammation as a discrete, present-or-absent process. Instead, aggregate findings mandate a reformed framework that can accommodate the innumerable variables of biological context. Such a revised framework is essential to restore functional relevance to otherwise mere markers of disease.

**Aberration versus adaptation: allostatic as an alternative construct to inflammation**

The challenge then arises to develop alternative paradigms capable of incorporating these findings that appear discordant within the current conceptual framework of inflammation. One such alternative construct is that of allostatics, a model initially applied to cardiovascular physiology and hypertension and subsequently expanded to describe the effects of chronic stress. In contradistinction to homeostasis, allostatics invokes continual adaptation and change rather than conservation of a single set point. Further, allostatic theory posits that these adaptations entail not only reactive but also anticipatory responses designed to optimize efficiency and, ultimately, survival and reproductive success. Importantly, however, allostatic theory does not assume that the new state of equilibrium will be identical to that achieved before stress. Allostatic load also can transition to a state of allostatic overload if the stressors become sufficiently chronic or the attendant energy requirements exceed energy intake. In states of allostatic overload, maladaptive or dysregulated responses now become evident. Further, even the adaptive responses to stress, particularly with prolonged stress, may themselves lead to seemingly adverse consequences and thereby contribute to allostatic load. Thus, in contrast to models of homeostasis, allostatic allows for physiologic recalibration of the biological system and creates conceptual space for adaptive responses that may result in new biological set points. Whereas homeostasis invokes linear and binary designations, allostatic is an intrinsically nonlinear model of biology. In contrast to allostatic theory, the reduction of immune system activation to a unitary concept— inflammation—and selected biomarkers can result in missed or erroneous biological insights and potentially dangerous translational efforts. Despite its putative anti-inflammatory effects, for example, the selective COX-2 inhibitor rofecoxib was found to confer a near doubling in cardiovascular event rate. Analogously, the paradigm of oxidative stress in the pathogenesis of cancer and cardiovascular disease has led to a number of clinical trials evaluating the efficacy of antioxidants in disease prevention. Strikingly, however, beta carotene supplementation among smokers resulted in increased risk of both lung cancer and cardiovascular disease.
score the potential dangers of prematurely translating observational or in vitro findings into clinical interventions and, moreover, highlight our relative paucity of mechanistic insight into the pathogenesis of many chronic diseases.

A second and related model, systems biology, views phenotype as the highly context-dependent output of integrated networks of cells and signaling molecules. Understanding these multipathway networks requires measurement of many targets across multiple cell types under many conditions. The fundamental insight of systems biology is that a physiologic system cannot be understood if examined in isolation or assessed under only one condition, even if thousands of variables are quantified. As such, the same stimulus may elicit different or opposite responses as a function of the state of the network. This phenomenon characterizes the functioning of genetic and brain networks and has been well recognized in neuroscience research but is now inarguably not unique to the field; as a rule, then, biological signals simply cannot be reliably interpreted independent of context.

**Conclusion**

Cytokine signaling is of enormous physiologic and pathophysiologic importance, with a vast and continuously expanding spectrum of described biological effects. The exquisite complexity of immune system function and its exquisitely complex relationship to the etiopathogenesis of metabolic and affective disorders simply cannot be captured through reductionist terms like “proinflammatory.” Rather, binary and linear models become increasingly devoid of meaning as they fail to evolve with emergent findings. Whereas inflammation once captured previously unrecognized roles of the immune system, it now promotes a physiologically inaccurate model that at best impedes understanding and at worst may lead to premature and potentially destructive therapeutic strategies. Our efforts to understand the role of immune signaling in depression and metabolic disease will be advanced only if informed by models that encourage the assignment of functional significance to biological mediators and recognize dynamic changes in biological context. Thus, discrete mediators can and do exert different effects in the presence or absence of other local signals, and these effects exhibit variable kinetics that may result in a single mediator performing seemingly disparate functions at different time points. As conceptual frameworks inform therapeutic strategies, investigative questions, and the interpretation of data, they must be continually reexamined and refined, particularly when emergent data consistently challenge the existing constructs. This reformulation of the immune system’s role in depression and metabolic disease is necessary to enable the continued growth of this extraordinarily promising area of investigation. Even more critical, our proposed reformulation offers a more textured approach to biology that could optimize treatment strategies and help avoid those with the potential to do greater harm than good.

**Acknowledgments/Conflict of Interest/Disclosures:** The authors are particularly grateful to Steven Hyman and Bruce McEwen for their insightful review and critique of this work, as well as to Sarah Johnson for her editorial assistance. The authors have no conflicts of interest to disclose. K. Rubinow is supported by NIH/NICHD grant 6K12HD053984 and a University of Washington Diabetes Research Center New Investigator Award P30 DK017047. D. Rubinow is supported by NIH/NIMH grants R01MH087619-05 and R01MH095992-01A1 and by the Foundation of Hope.

**REFERENCES**

1. Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population-based studies. *Obes Rev.* 2011;12(5):e438-e453.
2. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. *Mol Psychiatry.* 1999;4(4):317-327.
3. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. *J Clin Invest.* 2001;121(6):2111-2117.
4. Dominguetti CP, Duse LM, Carvalho M, de Souza LP, Gomes KB, Fernandes AP. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. *J Diabetes Complications.* 2016;30(4):738-745.
5. Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. *Eur Heart J.* 2016;37(22):1723-1732.
6. Hubbard JM, Cohen HJ, Muss HB. Incorporating biomarkers into cancer and aging research. *J Clin Oncol.* 2014;32(24):2611-2616.
7. Raison CL, Borsov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. *J Clin Psychiatry.* 2005;66(1):41-48.
8. Udina M, Castellví P, Moreno-España J, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. *J Clin Psychiatry.* 2012;73(8):1128-1138.
9. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-α: recognition and management. *CNS Drugs.* 2005;19(2):105-123.
10. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. *Depress Anxiety.* 2013;30(4):297-306.
11. DellaGoia N, Hannestad J. A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev. 2010;34(1):130-143.

12. Eisenberger NI, Inagaki TK, Mashal NM, Irwin MR. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun. 2010;24(4):558-563.

13. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010;68(8):748-754.

14. Hodes GE, Plau ML, Leboeuf M, et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci U S A. 2011;114(45):16136-16141.

15. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457.

16. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15(3):199-226.

17. Gola H, Engler H, Sommershof A, et al. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry. 2013;13:40.

18. Lindqvist D, Wolkowiz OM, Mellon S, et al. Proinflammatory milieu induces social phobia. Biol Psychiatry. 2014;75(1):59-67.

19. Newton TL, Fernandez-Botran R, Miller JJ, Burns VE. Interleukin-6 and soluble interleukin-6 receptor levels in posttraumatic stress disorder: associations with lifetime diagnostic status and psychological context. Biol Psychol. 2014;99:150-159.

20. Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry. 2015;2(11):1002-1012.

21. Maes M, Fišár Z, Medina M, Scapagnini G, Novak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–NFκB activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20(3):127-150.

22. Maes M, Song C, Yirmiya R. Targeting IL-1 in depression. Expert Opin Ther Targets. 2012;16(11):1097-1112.

23. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2012;69(12):112-213.

24. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep. 2011;13(6):467-475.

25. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.

26. Maachi M, Pleron L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα and IL-6 levels in obese women. Int J Obes Relat Metab Disord. 2004;28(8):993-997.

27. Curat CA, Miranville A, Sengénès C, et al. From blood monocytes to adipose tissue–resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes. 2004;53(5):1285-1292.

28. Nio Y, Yamauchi T, Iwabu M, et al. Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M1 macrophages and ameliorates insulin resistance and fatty liver in lipopolysaccharide diabetic A-ZIP transgenic mice. Diabetologia. 2012;55(12):3350-3358.

29. De Taeye BM, Novitskaya T, McGuinness OP, et al. Macrophage TNF-α contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab. 2007;293(3):E713-E725.

30. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 1997;389(6651):610-614.

31. Ruan H, Haochen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes. 2002;51(5):1319-1336.

32. Sethi JK, Xu H, Uysal KT, Wiesbrock SM, Scheja L, Hotamisligil GS. Characterisation of receptor-specific TNFα functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett. 2000;469(1):77-82.

33. Gao ZG, Ye JP. Why do anti-inflammatory therapies fail to improve insulin sensitivity? Acta Pharmacol Sin. 2012;33(2):182-188.

34. Ye J, McGuinness OP. Inflammation during obesity is not all bad: evidence from animal and human studies. Am J Physiol Endocrinol Metab. 2013;304(5):E466-E477.

35. Heeg LD, Sjøberg KA, Jeppesen J, et al. Lipid-induced insulin resistance affects women less than men and is not accompanied by inflammation or impaired proximal insulin signaling. Diabetes. 2011;60(1):64-73.

36. Matthews VB, Allen TL, Rissi S, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia. 2010;53(11):2431-2441.

37. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and ‘mood’ to interleukin-6 concentrations in patients with major depressive disorder. Mol Psychiatry. 2012;17(8):112-115.

38. Kubera M, Kenis G, Bosmans E, et al. Stimulatory effect of anti-inflammatory drugs on the production of IL-6. Int Immunopharmacol. 2004;4(2):185-193.

39. Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995;34(4):301-309.

40. Munzer A, Sack U, Mergl R, et al. Impact of antiinflammatory agents on cytokine production of depressed patients in vitro. Toxins (Basel). 2013;5(11):2227-2240.

41. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Anti-inflammatory effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A. 2011;108(2):9262-9267.

42. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep. 2011;13(6):467-475.
Clinical research

57. Kalinski P. Regulation of immune responses by prostaglandin E₂. J Immunol. 2012;188(1):21-28.
58. Mancini AD, Di Battista JA. The cardinal role of the phospholipase A₂/cyclooxygenase-2/prostaglandin E synthase/prostaglandin E₂ (PCPP) axis in inflammmostasis. Inflamm Res. 2011;60(12):1083-1092.
59. Park PH, McMullen MR, Huang H, Thakur V, Nagy LE. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-α (TNF-α) expression via ERK1/2 activation and Egr-1 expression: role of TNF-α in adiponectin-stimulated interleukin-10 production. J Biol Chem. 2007;282(30):21695-21703.
60. Ziegler-Heitbrock HW. Molecular mechanism in tolerance to lipopolysaccharide. J Immunol. 1995;45(1):13-26.
61. Peck OM, Williams DL, Breuel KF, et al. Differential regulation of cytokine and chemokine production in lipopolysaccharide-induced tolerance and priming. Cytokine. 2004;26(5):202-208.
62. McEwen BS, Gray J, Nasca C. Recognizing resilience: learning from the effects of stress on the brain. Neurobiol Stress. 2015;1:1-11.
63. Purvis JE, Lahav G. Encoding and decoding cellular information through signaling dynamics. Cell. 2013;152(5):945-956.
64. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem. 1997;272(2):971-976.
65. Salles J, Tardif N, Landrier JF, et al. TNFα gene knockout differentially affects lipid deposition in liver and skeletal muscle of high-fat-diet mice. J Nutr Biochem. 2012;23(12):1685-1693.
66. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341(10):738-746.
67. Pike JL, Irwin MR. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun. 2006;20(2):169-174.
68. McEwen BS, Gianaros PJ. Stress- and allostasis-induced brain plasticity. Annu Rev Med. 2011;62:431-445.
69. McEwen BS, Wingfield JC. What is in a name? Integrating homeostasis, allostasis and stress. Horm Behav. 2010;57(2):105-111.
70. Romero LM, Dickens MJ, Cyr NE. The Reactive Scope Model—a new model integrating homeostasis, allostasis, and stress. Horm Behav. 2009;55(3):375-389.
71. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
72. Omenn GS. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future. Eur J Cancer Prev. 2007;16(3):184-191.
73. Clarke DC, Lauffenburger DA. Multi-pathway network analysis of mammalian epithelial cell responses in inflammatory environments. Biochem Soc Trans. 2012;40(1):133-138.
Redefinición del papel del sistema inmunitario en la enfermedad crónica dentro de la defensa inmune

Durante la última década, el reconocimiento de la alteración de la función del sistema inmune en muchas enfermedades crónicas ha demostrado ser un avance central en la investigación biomédica. En diversos trastornos metabólicos y anímicos, esta actividad inmune alterada ha sido caracterizada como inflamación, asumiendo concomitantemente que la respuesta inmune es aberrante. Sin embargo, la evidencia acumulada desafía esta suposición y sugiere que el sistema inmune puede estar estructurando respuestas adaptativas a estresores crónicos. Además, un modelo simplista y binario no es capaz de dar cuenta de la excesiva complejidad de la función inmune ni hacer comprensibles los mecanismos internos esenciales. En este contexto, este artículo de perspectiva se propone entregar paradigmas alternativos para la comprensión del papel del sistema inmune en la enfermedad crónica. Al invocar la alostasis o la biología de sistemas antes que la inflamación, se puede atribuir un mayor significado funcional a los mediadores inmunes, obtener una nueva apreciación de los aspectos adaptativos de la actividad inmune alterada, y evitar mejor los efectos potencialmente desastrosos de traducir suposiciones erróneas en nuevas estrategias terapéuticas.

Vers une redéfinition du rôle du système immunitaire dans la maladie chronique

Ces 10 dernières années, l’identification d’une altération du système immunitaire dans de nombreuses maladies chroniques est au centre des avancées de la recherche biomédicale. Dans de nombreux troubles métaboliques ou de l’humeur, cette activité immunitaire modifiée se caractérise par une inflammation, ce qui suppose une réponse immunitaire anormale. Cette hypothèse est néanmoins mise en défaut car un nombre croissant d’arguments suggère que le système immunitaire développerait des réponses adaptatives aux facteurs de stress chroniques. De plus, un modèle simpliste, binaire, ne peut rendre compte de l’extraordinaire complexité de la fonction immunitaire et n’est pas suffisant pour en restituer les mécanismes fondamentaux. Dans ce contexte, nous proposons dans cet article d’autres modèles pour comprendre le rôle du système immunitaire dans la maladie chronique. En invoquant l’allostase ou la biologie de systèmes plutôt que l’inflammation, nous pouvons accorder une plus grande importance fonctionnelle aux médiateurs immunitaires, réviser notre conception des capacités d’adaptation d’une activité immunitaire altérée et mieux éviter les effets potentiellement désastreux d’une traduction d’hypothèses erronées en nouveaux traitements.